Zentalis reports median overall survival of 15.8 months with azenosertib in Cyclin E1-positive PROC
ZNTL•Zentalis Pharmaceuticals said median overall survival was 15.8 months with azenosertib in Cyclin E1-positive PROC. The data from DENALI Part 1B were published in an ESMO Congress 2026 abstract.
1. Survival data
Zentalis Pharmaceuticals announced first overall survival data for azenosertib from DENALI Part 1B, reporting median overall survival of 15.8 months in Cyclin E1-positive PROC. The data were published in an ESMO Congress 2026 abstract.
